Actively Recruiting
Feasibility Study of Empagliflozin and Ranolazine for Right Ventricular Failure in Pulmonary Hypertension
Led by University of Alberta · Updated on 2026-10-15
30
Participants Needed
5
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the feasibility of conducting a larger clinical trial aimed at improving right ventricular function in people with pulmonary hypertension and right heart failure. This phase 2, open-label, randomized control trial includes 30 participants who will be divided into three groups to compare the effects of empagliflozin or ranolazine combined with standard care against standard care alone. The purpose is to gather preliminary data to support a larger platform trial testing multiple treatment options. Participants will be randomly assigned to receive either empagliflozin 10 mg once daily plus standard care, ranolazine starting at 500 mg twice daily and increasing to 1000 mg twice daily after 2 weeks with dose adjustment if using certain medications plus standard care, or standard care alone. The study will track participant outcomes for 16 weeks after randomization to assess feasibility and collect data on right ventricular function and related health measures. During the 16-week study period, participants will have their medical records reviewed to assess various outcomes, including enrollment rates, follow-up success, and data collection ability. Researchers will evaluate heart function, exercise capacity through virtual and in-person tests, and quality of life using questionnaires. Safety and clinical events will also be monitored to inform the design of future larger trials.
CONDITIONS
Brief Title
Feasibility Trial for a Right Ventricular Failure Platform Trial
Research Team
J
Jason Weatherald, MD,MSc,FRCPC
C
Courtney Gubbels, BA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here